Innate Pharma

Cécile Bonnafous

Hélène Sicard

Renaud Buffet

Mathieu Blery

Laurent Gauthier

Carine Paturel

Nadia Anceriz

Ivan Perrot

Yannis Morel

Arnaud Dujardin

The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma

The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.

Treatment of peripheral T cell lymphoma

Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.

TLR3 binding agents

Growing community of inventors

Marseilles, France

Cécile Bonnafous